Pneumococcal vaccination in persons living with HIV: Pneumococcal conjugate, polysaccharide or both?

Dhingra, Bhavna; Singh, Sarman

doi:10.1016/j.eclinm.2020.100593

Cited by 3 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Persons with HIV (PWH) have a more than thirty-fold increased risk of pneumococcal infections, which are a leading cause of morbidity and mortality (Dhingra & Singh, 2020; Garmpi et al, 2019), even though the cost of vaccinations is relatively low, on average less than $250 (Centers for Disease Prevention and Control, 2023).…”

Section: Problem Descriptionmentioning

confidence: 99%

A System Intervention to Increase Pneumococcal Vaccination Rates in Adults Living With Human Immunodeficiency Virus Who Present for Scheduled Medical Care

Jensen,

Waldrop,

Derouin

et al. 2024

J Assoc Nurses AIDS Care

View full text Add to dashboard Cite

Pneumococcal vaccinations are recommended for adults living with HIV; however, eligibility criteria are complex. At a clinic specializing in the care of lesbian, gay, bisexual, transgender, or queer/questioning persons, only 36% of patients who were vaccine-eligible received the vaccination. A set of decision trees was developed to guide clinic personnel in determining whether a vaccine is recommended. The provider then determined whether the vaccine was appropriate based on each patient's complete clinical presentation. When appropriate, patients were offered the vaccine at the same appointment. This practice change led to a 22% increased vaccination rate.

show abstract

Section: Problem Descriptionmentioning

confidence: 99%

A System Intervention to Increase Pneumococcal Vaccination Rates in Adults Living With Human Immunodeficiency Virus Who Present for Scheduled Medical Care

Jensen,

Waldrop,

Derouin

et al. 2024

J Assoc Nurses AIDS Care

View full text Add to dashboard Cite

show abstract

“…Although evidence is lacking, the current UK recommendation is for sequential vaccination with PCV13 followed by PPV23 to induce and maintain protective immunity [ 30 ]. There is growing evidence to delay PCV13 vaccination until after recovery of CD4 T cell count (>200 cells/mm 3 ) due to the immunology of T- cell dependent versus T- cell independent vaccines [ 24 ].…”

Section: Secondary Immunodeficiencymentioning

confidence: 99%

Pneumococcal Vaccination in Immunocompromised Hosts: An Update

2021

View full text Add to dashboard Cite

Infections with the pathogen, Streptococcus pneumoniae, are a common cause of morbidity and mortality worldwide. It particularly affects those at the extremes of age and immunocompromised individuals. Preventing pneumococcal disease is paramount in at risk individuals, and pneumococcal vaccination should be offered. Here, we discuss the role of pneumococcal vaccination in specific groups of immunocompromised hosts.

show abstract

“…Equally, illness prevention is crucial in maintaining a healthy and symptom‐free lifespan. Preventative medications such as statins are likely to play a role in some [18], exercise and maintaining active social connections are important for all [19], and vaccination to reduce the incidence of vaccine‐preventable diseases such as influenza and pneumococcal disease will reduce the incidence of severe disease, hospitalization, and secondary post viral complications [20]. Shingles can also lead to disfigurement, chronic pain, and secondary infection, the incidence of which can be dramatically reduced through appropriate zoster vaccination, which has advanced significantly in recent years, as described by Dauby et al, such that more people living with HIV can safely receive vaccination if they choose [21].…”

mentioning

confidence: 99%